GLP-1/GIP

Tirzepatide

Also known as Mounjaro, Zepbound

Tirzepatide (Mounjaro/Zepbound) is a weekly injection that hits two gut hormones at once (GIP and GLP-1), making it especially strong at cutting appetite and lowering blood sugar for diabetes and weight loss.

One-dose burn-down
Half-life
5.0 days
Range
4.6 days–5.4 days
Tmax
24 h
Bioavailability
80%
Steady state
~28d
Typical dose
2.5 mg

Dual GIP and GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and weight management (Zepbound). Once-weekly subcutaneous injection.

Mechanism of action

Activates both GIP and GLP-1 receptors, amplifying glucose-dependent insulin secretion and appetite suppression with strong weight-loss effect.

Boxed warning for thyroid C-cell tumors. ~5-day half-life → ~4 weeks to steady state. Titrate monthly.

Track Tirzepatide for free

Log your doses and PeptideBuddy models Tirzepatide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.

Start tracking free
FDA Prescribing Information (DailyMed)

Related GLP-1/GIP